There are 3164 resources available
How to define pathologic response?
Presenter: Judith Bovée
Session: Definition and clinical implication of response in localised sarcomas
Resources:
Slides
Webcast
Invited Discussant LBA4
Presenter: Marleen Kok
Session: Presidential Symposium II: Practice-changing trials
Resources:
Slides
Webcast
1537O - Value of immune checkpoint blockade (ICB) in microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC)
Presenter: Benjamin Geisler
Session: Proffered paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
231O - Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase III UNICANCER trial
Presenter: Sofia Rivera
Session: Presidential Symposium II: Practice-changing trials
Resources:
Abstract
Slides
Webcast
The advantages of boosting studies to increase drug exposure of anticancer drugs
Presenter: Nielka Van Erp
Session: Current advances in clinical pharmacology within oncology, and its relevance for daily practice
Resources:
Slides
Webcast
Enhancing the checkpoints' activity in pMMR
Presenter: Vicky Makker
Session: What we know and what we should know on immunotherapy and endometrial cancer (EC)
Resources:
Slides
Webcast
The radiologist point of view
Presenter: Wolfgang Kunz
Session: Definition and clinical implication of response in localised sarcomas
Resources:
Slides
Webcast
Cost-effectiveness of optimized immunotherapy dosing
Presenter: Marzia Del Re
Session: Current advances in clinical pharmacology within oncology, and its relevance for daily practice
Resources:
Slides
Webcast
Invited Discussant 1535O, 1536O and 1537O
Presenter: Dario Trapani
Session: Proffered paper session: Policy and preventive strategies
Resources:
Slides
Webcast
Overcoming the resistance to IO: What can we do?
Presenter: Frederik Marmé
Session: What we know and what we should know on immunotherapy and endometrial cancer (EC)
Resources:
Slides
Webcast